Skip to content

A phase I/II study of percutaneous radiofrequency ablation for osteoid osteoma (JIVROSG-0704)

A phase I/II study of percutaneous radiofrequency ablation for osteoid osteoma (JIVROSG-0704) - Percutaneous radiofrequency ablation for osteoid osteoma (JIVROSG-0704)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001501
Enrollment
21
Registered
2008-11-12
Start date
2008-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoid osteoma

Interventions

Following the percutaneous insertion of a radiofrequency needle, radiofrequency ablation of nidus of osteoid osteoma is to be performed.

Sponsors

Japan Interventional Radiology in Oncology Study Group (JIVROSG)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Clinically or radiographically diagnosed osteoid osteoma. 2) Target lesion (i.e. nidus) is visualized with CT. 3) Not a candidate for surgery or refuse surgery. 4) Oral analgesic use for pain control of osteioid osteoma. 5) Adequate cardiac, hepatic, renal, respiratory, coagulation, and bone marrow functions. 6) Performans status of 0-2. 7) Written informed consent from the patient or the delegate.

Exclusion criteria

Exclusion criteria: 1) Cardiac pacemaker. 2) Vital artery or nerve on the needle route. 3) Vital neural structures in the field of ablation. 4) Maximum diameter of the target lesion (i.e. nidus) > 1.5cm. 5) Pretreatment Visual Analogue Scale < 2. 6) Previous locoregional treatment for the target lesion. 7) Not applicable for anesthesia (general, spinal, or epidural). 8) Pregnant. 9) Not eligible determined by the responding physician.

Design outcomes

Primary

MeasureTime frame
Safety.

Countries

Japan

Contacts

Public ContactYasuaki Arai

JIVROSG, Coordinating Office Division of Diagnostic Radiology, National Cancer Center Hospital

jivrosgoffice@ml.res.ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026